Skip to main content
Dosing initiated in late-stage trial for combo therapy in myeloma

I-Mab Biopharma and MorphoSys have begun dosing patients in a late-stage study to assess the safety and efficacy of MorphoSys' investigational antibody MOR202 in combination with Revlimid, or lenalidomide, and dexamethasone to treat relapsed or refractory multiple myeloma. The study is being conducted in Taiwan, and its results will be used to support the filing of a biologics license application in China.

Full Story: